The global hepatitis test solution/diagnosis market is expected to grow at an approximate CAGR of 4.9% during forecast period, 2018–2023.
Hepatitis is a liver infection caused by the hepatitis virus and results to cause liver inflammation, or sometimes liver damage. There is different type of hepatitis infection such as hepatitis A, hepatitis B, and hepatitis C which cause this infection. This pathological infection spreads through contaminated blood, infected medical devices and lasts for several years.
The patient suffering from hepatitis infection faces many symptoms such as poor appetite, weakness, weight loss, itching on skin, jaundice, dark-coloured urine, swelling on legs, drowsiness and many more. The key factors responsible to drive the market are rising awareness regarding the disease, growing adoption of innovative technologies, and increasing health care expenditure.
ALSO READ :https://teletype.in/@marketresearchmrfr/1nP2dnfrO
According to the World Health Organization (WHO) 2018 fact sheet, it was estimated that 71 million population across the globe have chronic hepatitis C and it was also mentioned that approximately 399,000 number of people die each year from hepatitis infection. Such a large population affected by hepatitis infection boosts the market growth.
However, the factors such as side effects associated with the medications and treatment are expected to hinder the market growth.
Segmentation
The global hepatitis test solution diagnosis market is segmented on the basis of disease type, technology, end user and region.
On the basis of disease type, the market is segmented into Hepatitis A, Hepatitis B, Hepatitis C and others.
The global hepatitis test solution/diagnosis market by technology is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT) and others.
On the basis of end-user, the market is categorized into hospital & diagnostic laboratories, blood banks and other.
Regional Analysis
The Americas dominates the global market for hepatitis test solution/diagnosis owing to the increasing awareness about hepatitis infection and various symptoms associated to it, rising geriatric population, and presence of major market players within the region. Additionally, the rising economy and high expenditure on healthcare sector within the region fuels the market growth during the forecast period. In 2017, it was estimated that Europe stood second in the global hepatitis test solution/diagnosis market due to increasing prevalence of hepatitis infection, kidney problem and other infectious diseases within the region. Asia Pacific was the fastest growing region for the global hepatitis test solution/diagnosis market in 2017. Factors such as increasing awareness about the treatment methods, adoption of new technology, rapidly developing healthcare within the region drives the market growth within the region. On the other hand, the Middle East and Africa holds a least share in the global hepatitis test solution/diagnosis market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East.
Key Players
Some of the key players in the global hepatitis test solution/diagnosis market are Abbott Laboratories Inc. (US), BiomérieuxSa (France), Bio-Rad Laboratories (US), Danaher Corporation (US), Diasorin (Italy), Fujirebio, Inc. (Japan), Grifols (USA), MedMira, Inc. (US), Qiagen (UK), Roche Diagnostics (UK), Siemens Healthineers (UK) and Others.
NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
AkashAnand
Market Research Future
+1 646 845 9312
Email: [email protected]
Become an antibodie, infectious disease donor with Access Clinical by participating in paid blood, plasma donation studies program.
We will compensate for your time and blood donation.
The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.
The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.
Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnosticsDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589Global Market Segmentation:The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service.
The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period.
The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases.
The hepatitis diagnostics segment accounted for the largest share of the global market in 2017.
Global Bone pain treatment Market - OverviewThe pain caused in the bone due to any reason is known as bone pain.
According to International Osteoporosis Foundation, globally osteoporosis causes more than 8.9 million fractures annually and resulting in an osteoporotic fracture every 3 seconds.
However, side effects of the drugs and expensive R activates has hampered the growth of the market.The market is forecasted to demonstrate a high growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017 – 2023.Global bone pain treatment market is expected to grow at a CAGR of 9.8% during forecasted period 2017-2023.Global Bone pain treatment Market -SegmentationGlobal bone pain treatment is segmented on the basis of condition, into bone cancer, osteoporosis, infectious diseases and other.
Primary bone cancer is sub segmented into osteosarcoma, chondrosarcoma, ewing tumor and other.On the basis of treatment, the market is segmented into drug treatment, cryosurgery, radiotherapy, surgical treatment.
And on the basis of end users, they are segmented into hospitals, clinics and other.Global Bone pain treatment Market - Competitive AnalysisCharacterized by the presence of several well-established and small players, the global market of Bone pain treatment appears to be highly competitive and fragmented.
With well-established market in the Americas region major companies like Eli Lilly and Company, Amneal Pharmaceuticals LLC, Amgen, Inc, Actavis plc, Pfizer Inc, and various others have their home in the region and generate maximum market share.
